Chris Molloy, CEO of the Medicines Discovery Catapult, one of the latest members of the UK’s Catapult network, explains why SMEs are set to power future medicines development. We are familiar ...

President Donald Trump has nominated another candidate to lead the CDC – acting director Susan Monarez – after withdrawing support for his first choice a couple of weeks ago. Monarez replaces ...

In clinical research, there is no such thing as ‘taking a leap of faith’ and yet the industry’s need for empirical certainty can sometimes thwart adoption of important innovation ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

PT: How does pharma deal with diverse geographies during launch? AH: This is difficult! Local and national reimbursement environments vary significantly by country and many will reference ...

“If I had asked people what they wanted, they would have said faster horses.” This quote, often linked to Henry Ford (though its authenticity is debated), has become a go-to argument for ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

This is your prime opportunity to connect with leadership professionals in biopharma responsible for attracting, retaining and developing the talent necessary deliver on their organizations mission.

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic development. From computational target discovery to novel molecular mechanisms ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read on for our round-up of both Board of Director and Advisory Board hires.

Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of drugs for progressive vision disorders, starting with age-related ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.